Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer.
Annelieke A LemijNienke A de GlasMarloes G M DerksEsther BastiaannetJos W S MerkusTitia E LansCarmen C van der PolThijs van DalenAnnelie J E VulinkLeander van GervenOnno R GuicheritEugenie M H Linthorst-NiersFrederiek van den BosJudith R KroepGerrit Jan LiefersJohanneke E A PortieljePublished in: Breast cancer research and treatment (2022)
A large proportion of older patients discontinue adjuvant endocrine treatment within 2 years after initiation, but geriatric characteristics are not predictive of early discontinuation of treatment. Discontinuation of adjuvant endocrine therapy did not positively affect QoL and functional status, which implies that the observed poorer QoL in this group is probably not caused by adverse effects of endocrine therapy.